Ampio Pharmaceuticals, Inc. discovers and develops drugs for metabolic, eye, kidney, inflammation, and central nervous system diseases. The company's principal products include Optina, an oral drug that is in Phase II clinical trials for the treatment of diabetic retinopathy and macular edema; and Vasaloc, an oral drug in Phase II clinical trials for the treatment of diabetic nephropathy. It is also developing DMI-9523, a new molecular entity being developed as a non-steroidal oral drug for the treatment of diseases involving inflammation. Ampio Pharmaceuticals, Inc. was formerly known as DMI Life Sciences, Inc. and changed its name to Ampio Pharmaceuticals, Inc. in March 2010. Ampio Pharmaceuticals, Inc. was founded in 1990 and is based in Greenwood Village, Colorado.